|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Finding new therapeutic targets for modulating specifically GPER1 in breast tumors may improve endocrine breast cancer therapy.
|
31082617 |
2019 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This review addresses the signaling of ERβ and GPER in ERα-negative breast tumors.
|
30687231 |
2018 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
It is noteworthy that the potential of GPER to mediate stimulatory effects of estrogens has been also shown in CAFs derived from patients with breast tumors, suggesting that GPER may act at the cross-road between cancer cells and these important components of the tumor microenvironment.
|
28249728 |
2018 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
It has been largely reported that the classical estrogen receptor (ER), as well as the G protein estrogen receptor (GPER, previously known as GPR30) can exert a main role in the development of breast tumors.
|
27341075 |
2017 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Analysis of TCGA RNAseq data revealed significantly lower mean expression of GPER1 mRNA in primary breast tumors compared to that in normal breast tissues.
|
28286086 |
2017 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We first determined that GPER is co-expressed with IGF1R and with the vessel marker CD34 in human breast tumors (n = 4972).
|
29212519 |
2017 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
As tamoxifen via GPER induced aromatase expression also in CAFs, this pathway may be involved in promoting aggressive behavior of breast tumors in response to tamoxifen treatment.
|
24928526 |
2014 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis.
|
24440569 |
2014 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
GPER1 expression was analyzed by immunohistochemistry in breast tumors from 273 pre- and postmenopausal stage II patients, all treated with adjuvant tamoxifen for 2 years (cohort I) and from 208 premenopausal lymph node-negative patients, of which 87% were not subjected to any adjuvant systemic treatment (cohort II).
|
23554355 |
2013 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
On the basis of our results, the action of EGF may include the up-regulation of GPR30 in facilitating a stimulatory role of estrogen, even in ER-negative breast tumor cells.
|
18467441 |
2008 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Association of the membrane estrogen receptor, GPR30, with breast tumor metastasis and transactivation of the epidermal growth factor receptor.
|
18289622 |
2008 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells.
|
15090535 |
2004 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer.
|
11897506 |
2002 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Our data imply that ER-negative breast tumors that continue to express GPR30 may use estrogen to drive growth factor-dependent cellular responses.
|
11043579 |
2000 |